Chengda Biology: Net profit in 2025 compared to the previous year dropped by 61.56%, planning to distribute a cash dividend of 1 yuan per 10 shares.

On April 20th, Chengda Biology disclosed its annual report, achieving a operating income of 1.39 billion yuan in 2025, a decrease of 17.06% year-on-year; the net profit attributable to the parent company's shareholders was 132 million yuan, a decrease of 61.56% year-on-year. The company plans to distribute a cash dividend of 1 yuan per 10 shares. During the reporting period, the operating performance was mainly affected by the following factors: firstly, in terms of operating income, the company's domestic and foreign sales revenue showed structural differentiation. Due to factors such as intensified industry competition, proactive destocking by channels, and standardized adjustments in rabies outbreak prevention and control work, domestic sales revenue decreased; while foreign sales revenue achieved steady growth, partially offsetting the aforementioned impact. Secondly, in terms of net profit, in addition to the decrease in operating income, factors such as increased impairment losses, decreased selling and management expenses, and increased fair value change income collectively influenced profit performance. Thirdly, in terms of cash flow, the net cash flow generated from operating activities by the company was 341 million yuan, a decrease of 31.96% year-on-year, mainly due to a decrease in sales collections.